Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for NEO

Stock NameNeo Energy Metals Plc
TickerNEO(GBP) LSE
TYPECommon Stock
CountryUK
ISINGB00BYWLRL80
LEI213800WE14587VRQ5Y10

Show aggregate NEO holdings

News associated with NEO

Stephens Forecasts Strong Price Appreciation for NeoGenomics (NASDAQ:NEO) Stock
NeoGenomics (NASDAQ:NEO – Get Free Report) had its target price boosted by equities researchers at Stephens from $6.50 to $11.00 in a note issued to investors on Tuesday, Marketbeat.com reports. The firm currently has an “overweight” rating on the medical research company’s stock. Stephens’ price target points to a potential upside of 34.31% from the […] - 2025-09-04 04:42:49
NeoGenomics (NASDAQ:NEO) Price Target Raised to $14.00
NeoGenomics (NASDAQ:NEO – Free Report) had its price target upped by Needham & Company LLC from $8.00 to $14.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the medical research company’s stock. Several other brokerages have also recently commented on NEO. Wall Street Zen upgraded shares of […] - 2025-09-01 02:59:14
Maryland State Retirement & Pension System Decreases Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Maryland State Retirement & Pension System trimmed its position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 13.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,401 shares of the medical research company’s stock after selling 5,877 shares […] - 2025-08-17 05:21:02
Stifel Nicolaus Forecasts Strong Price Appreciation for Neo Performance Materials (TSE:NEO) Stock
Neo Performance Materials (TSE:NEO – Get Free Report) had its price objective hoisted by investment analysts at Stifel Nicolaus from C$17.50 to C$22.00 in a research report issued on Wednesday,BayStreet.CA reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 30.41% from the company’s […] - 2025-08-15 02:14:50
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of “Hold” by Brokerages
Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) have earned a consensus rating of “Hold” from the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target […] - 2025-08-12 04:43:02
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Blair William & Co. IL
Blair William & Co. IL trimmed its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 25.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 65,638 shares of the medical research company’s stock after selling 22,312 shares during the quarter. Blair William […] - 2025-08-11 05:52:55
Harbour Investments Inc. Reduces Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Harbour Investments Inc. reduced its stake in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 50.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 2,835 shares of the medical research company’s stock after selling 2,937 shares during the period. Harbour Investments Inc.’s holdings in NeoGenomics were worth $27,000 as of its most recent SEC filing. […] - 2025-08-11 05:14:54
NeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by Federated Hermes Inc.
Federated Hermes Inc. increased its position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 10.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 161,428 shares of the medical research company’s stock after acquiring an additional 15,887 shares during the period. […] - 2025-08-06 05:16:55
Piper Sandler Issues Pessimistic Forecast for NeoGenomics (NASDAQ:NEO) Stock Price
NeoGenomics (NASDAQ:NEO – Get Free Report) had its price objective decreased by Piper Sandler from $12.00 to $11.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. Piper Sandler’s target price indicates a potential upside of 95.73% from the stock’s previous close. […] - 2025-08-06 02:18:47
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by TD Asset Management Inc
TD Asset Management Inc cut its holdings in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 57.5% during the first quarter, HoldingsChannel reports. The firm owned 89,910 shares of the medical research company’s stock after selling 121,522 shares during the period. TD Asset Management Inc’s holdings in NeoGenomics were worth $853,000 as of its most recent […] - 2025-08-05 05:32:52
NeoGenomics (NASDAQ:NEO) Given Market Perform Rating at William Blair
William Blair reaffirmed their market perform rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a report published on Tuesday, MarketBeat.com reports. A number of other equities analysts also recently commented on NEO. Leerink Partners downgraded NeoGenomics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock […] - 2025-07-30 04:34:56
NeoGenomics (NASDAQ:NEO) Hits New 52-Week Low Following Weak Earnings
NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday following a dissappointing earnings announcement. The company traded as low as $5.00 and last traded at $5.41, with a volume of 1442341 shares trading hands. The stock had previously closed at $6.46. The medical research company reported ($0.08) […] - 2025-07-30 02:14:46
VBK's Underlying Holdings Could Mean 12% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 08:27:30
Nisa Investment Advisors LLC Has $177,000 Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)
Nisa Investment Advisors LLC lowered its stake in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 56.7% in the first quarter, Holdings Channel.com reports. The institutional investor owned 18,698 shares of the medical research company’s stock after selling 24,517 shares during the quarter. Nisa Investment Advisors LLC’s holdings in NeoGenomics were worth $177,000 as of its […] - 2025-07-18 05:13:01
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Illinois Municipal Retirement Fund
Illinois Municipal Retirement Fund lessened its holdings in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 5.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 63,233 shares of the medical research company’s stock after selling 3,533 shares during the quarter. Illinois […] - 2025-07-04 04:46:51
Neo Performance Materials (TSE:NEO) Hits New 1-Year High After Dividend Announcement
Neo Performance Materials Inc. (TSE:NEO – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday after the company announced a dividend. The company traded as high as C$12.81 and last traded at C$12.54, with a volume of 171331 shares trading hands. The stock had previously closed at C$12.27. The newly announced […] - 2025-06-20 02:10:48
ProShare Advisors LLC Increases Position in NeoGenomics, Inc. (NASDAQ:NEO)
ProShare Advisors LLC increased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 44.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,445 shares of the medical research company’s stock after purchasing an additional 11,831 shares during the quarter. […] - 2025-05-26 05:49:09
Tower Research Capital LLC TRC Cuts Stake in NeoGenomics, Inc. (NASDAQ:NEO)
Tower Research Capital LLC TRC cut its stake in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 80.8% during the 4th quarter, HoldingsChannel reports. The firm owned 2,449 shares of the medical research company’s stock after selling 10,292 shares during the quarter. Tower Research Capital LLC TRC’s holdings in NeoGenomics were worth $40,000 as of its […] - 2025-05-14 04:24:47
Neo Performance Materials (TSE:NEO) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says
Neo Performance Materials (TSE:NEO – Get Free Report) had its target price boosted by equities research analysts at Stifel Nicolaus from C$16.50 to C$17.50 in a research report issued to clients and investors on Monday,BayStreet.CA reports. Stifel Nicolaus’ price target would suggest a potential upside of 58.80% from the stock’s current price. Neo Performance Materials […] - 2025-05-14 02:24:49
Schonfeld Strategic Advisors LLC Sells 54,330 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Schonfeld Strategic Advisors LLC cut its position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 76.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 16,280 shares of the medical research company’s stock after selling 54,330 shares during the period. Schonfeld Strategic Advisors LLC’s holdings in NeoGenomics were worth $268,000 as of its […] - 2025-05-13 05:42:51
NeoGenomics (NASDAQ:NEO) Upgraded to Hold at StockNews.com
NeoGenomics (NASDAQ:NEO – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday. Other equities research analysts also recently issued reports about the company. The Goldman Sachs Group cut their price target on NeoGenomics from $15.00 to $10.00 and set a […] - 2025-05-13 04:28:54
Voya Investment Management LLC Sells 5,003,158 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Voya Investment Management LLC trimmed its stake in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 98.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,688 shares of the medical research company’s stock after selling 5,003,158 shares during the quarter. Voya […] - 2025-05-07 05:57:02
Hsbc Holdings PLC Trims Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Hsbc Holdings PLC reduced its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 7.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,569 shares of the medical research company’s stock after selling 2,430 shares during the quarter. Hsbc Holdings PLC’s holdings […] - 2025-05-07 04:56:56
Needham & Company LLC Issues Pessimistic Forecast for NeoGenomics (NASDAQ:NEO) Stock Price
NeoGenomics (NASDAQ:NEO – Get Free Report) had its price objective decreased by research analysts at Needham & Company LLC from $18.00 to $8.50 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Needham & Company LLC’s target price would indicate a potential upside […] - 2025-05-01 02:52:52
NeoGenomics (NASDAQ:NEO) Shares Gap Down Following Weak Earnings
NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report)’s share price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $9.97, but opened at $9.64. NeoGenomics shares last traded at $7.59, with a volume of 85,531 shares changing hands. The medical research company reported ($0.08) earnings per […] - 2025-04-30 03:12:52
Barclays PLC Has $3.95 Million Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Barclays PLC increased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 239,438 shares of the medical research company’s stock after buying an additional 8,537 shares during the quarter. Barclays PLC […] - 2025-04-28 05:34:55
Invesco Ltd. Decreases Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Invesco Ltd. reduced its position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 6.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 410,967 shares of the medical research company’s stock after selling 27,789 shares during the quarter. Invesco Ltd. owned approximately 0.32% […] - 2025-04-25 05:08:53
Surprising Analyst 12-Month Target For RWJ
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-24 08:26:04
Sterling Capital Management LLC Grows Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Sterling Capital Management LLC lifted its position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 788.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,706 shares of the medical research company’s stock after buying an additional 3,289 shares during the period. […] - 2025-04-24 05:46:54
Rockefeller Capital Management L.P. Acquires 16,831 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Rockefeller Capital Management L.P. grew its holdings in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 49.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,082 shares of the medical research company’s stock after acquiring an additional 16,831 shares during the period. Rockefeller Capital […] - 2025-04-23 05:41:01

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc NEO holdings

DateNumber of NEO Shares HeldBase Market Value of NEO SharesLocal Market Value of NEO SharesChange in NEO Shares HeldChange in NEO Base ValueCurrent Price per NEO Share HeldPrevious Price per NEO Share Held
2025-09-26 (Friday)79,231USD 628,302USD 628,302
2025-09-25 (Thursday)79,231USD 623,152NEO holding decreased by -396USD 623,1520USD -396 USD 7.865 USD 7.87
2025-09-24 (Wednesday)79,231USD 623,548USD 623,548
2025-09-17 (Wednesday)78,717USD 638,395NEO holding increased by 9446USD 638,3950USD 9,446 USD 8.11 USD 7.99
2025-09-16 (Tuesday)78,717USD 628,949USD 628,949
2025-09-12 (Friday)78,203USD 622,496USD 622,496
2025-09-11 (Thursday)78,203USD 652,213USD 652,213
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NEO by Blackrock for IE00B3VWM098

Show aggregate share trades of NEO

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-08-21SELL-257 6.180* 10.55 Profit of 2,710 on sale
2025-07-31BUY771 4.840* 10.61
2025-06-30SELL-514 7.310* 11.10 Profit of 5,705 on sale
2025-06-25SELL-257 7.180* 11.18 Profit of 2,873 on sale
2025-06-20SELL-514 7.000* 11.27 Profit of 5,792 on sale
2025-05-23BUY257 7.410* 11.92
2025-05-19SELL-257 8.060* 12.07 Profit of 3,102 on sale
2025-05-15SELL-771 7.840* 12.14 Profit of 9,360 on sale
2025-05-12SELL-257 8.510* 12.24 Profit of 3,147 on sale
2025-05-09SELL-257 8.050* 12.28 Profit of 3,157 on sale
2025-04-30SELL-257 6.395* 12.60 Profit of 3,239 on sale
2025-04-24SELL-514 10.090* 12.74 Profit of 6,548 on sale
2025-04-17SELL-257 9.550* 12.90 Profit of 3,316 on sale
2025-04-15SELL-771 9.500* 12.98 Profit of 10,004 on sale
2025-04-14SELL-771 9.720* 13.01 Profit of 10,032 on sale
2025-04-09SELL-1,028 9.120* 13.14 Profit of 13,512 on sale
2025-04-07SELL-1,799 8.830* 13.25 Profit of 23,840 on sale
2025-04-04SELL-2,580 8.780* 13.30 Profit of 34,326 on sale
2025-03-31BUY258 9.490* 13.45
2025-03-19SELL-516 9.950* 13.84 Profit of 7,142 on sale
2025-03-14SELL-1,548 9.825* 14.01 Profit of 21,694 on sale
2025-03-13SELL-516 9.520* 14.08 Profit of 7,264 on sale
2025-03-12SELL-8,772 10.230* 14.13 Profit of 123,983 on sale
2025-03-07SELL-516 10.100* 14.32 Profit of 7,390 on sale
2025-03-06SELL-774 10.540* 14.38 Profit of 11,129 on sale
2025-03-03SELL-259 9.580* 14.61 Profit of 3,783 on sale
2025-02-28SELL-1,554 9.990* 14.68 Profit of 22,815 on sale
2025-02-26SELL-259 10.400* 14.84 Profit of 3,843 on sale
2025-02-25SELL-777 10.880* 14.90 Profit of 11,581 on sale
2025-02-18BUY1,295 12.405* 15.19
2025-02-13BUY259 13.910* 15.25
2025-02-12BUY259 13.780* 15.28
2025-02-11BUY777 13.480* 15.32
2025-02-06BUY2,322 13.490* 15.44
2025-01-27BUY258 15.040* 15.65
2024-12-30BUY1,290 16.920* 15.64
2024-12-06BUY1,032 17.760* 15.40
2024-12-05BUY258 17.190* 15.34
2024-12-04BUY1,290 18.010* 15.24
2024-11-29BUY1,290 17.730* 14.93
2024-11-27BUY1,032 17.740* 14.68
2024-11-26BUY258 17.180* 14.57
2024-11-21BUY1,290 15.390* 14.31
2024-11-20BUY771 15.360* 14.25
2024-11-18BUY3,084 15.010* 14.13
2024-11-12BUY2,056 16.330* 13.98
2024-11-08BUY1,285 15.770* 13.86
2024-11-07BUY3,855 15.820* 13.70
2024-11-06BUY514 15.460* 13.56
2024-10-31BUY257 13.590* 13.25
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NEO

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19231,4330663,13034.9%
2025-09-18403,0220949,14042.5%
2025-09-17290,75302,536,22211.5%
2025-09-16170,8580439,50238.9%
2025-09-15389,16811,846,00321.1%
2025-09-12259,918886717,77836.2%
2025-09-11435,5381451,116,86539.0%
2025-09-10235,763860527,56344.7%
2025-09-09297,1870493,66160.2%
2025-09-08323,514562551,07858.7%
2025-09-05211,7750461,51345.9%
2025-09-04443,96990943,71247.0%
2025-09-03650,2015,8771,476,97644.0%
2025-09-021,043,8441312,012,76551.9%
2025-08-292,044,58725,0514,468,08445.8%
2025-08-28351,2460994,99235.3%
2025-08-27342,0010771,16144.3%
2025-08-26210,1271,145489,98442.9%
2025-08-25224,9250686,97332.7%
2025-08-22196,4841,900631,65731.1%
2025-08-21118,4192,557314,00237.7%
2025-08-20118,1371,262334,25835.3%
2025-08-1988,200500334,43226.4%
2025-08-18108,6730479,89622.6%
2025-08-15229,6360485,01147.3%
2025-08-14149,0630399,19037.3%
2025-08-13150,9194,206473,31731.9%
2025-08-12250,24013,664698,44235.8%
2025-08-11253,103654792,36731.9%
2025-08-08209,748679661,21331.7%
2025-08-07248,5231,162696,34035.7%
2025-08-06200,287111524,54438.2%
2025-08-05259,9140910,81428.5%
2025-08-04315,14318,7651,067,21229.5%
2025-08-01507,2155711,592,22231.9%
2025-07-31675,56701,627,46441.5%
2025-07-30609,96616,6553,677,28416.6%
2025-07-291,671,621184,3706,062,51827.6%
2025-07-28409,3996491,227,78333.3%
2025-07-25141,8420512,51927.7%
2025-07-24107,988200594,74818.2%
2025-07-23130,5211864,78815.1%
2025-07-22140,0866,138663,58821.1%
2025-07-21166,0860589,95428.2%
2025-07-18262,161114523,62250.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.